Literature DB >> 15044352

Mechanisms underlying growth hormone effects in augmenting nitric oxide production and protein tyrosine nitration during endotoxin challenge.

Ted H Elsasser1, Stanislaw Kahl, Carol MacLeod, Benjamin Nicholson, James L Sartin, Congjun Li.   

Abstract

The present study defined the effects of GH administration on components of the nitric oxide (NO)-generating cascade to account for observed increases in NO production and protein nitration after an immune challenge. Calves were assigned to groups with or without GH treatment (100 microg GH/kg body weight or placebo im, daily for 12 d) and with or without low-level endotoxin [lipopolysaccharide (LPS), 2.5 microg/kg, or placebo, iv]. Plasma was obtained for estimation of NO changes as [NO(2)(-) + NO(3)(-)] (NO(x)). Transcutaneous liver biopsies were collected for measurement of protein tyrosine nitration, cationic amino acid transporter (CAT)-2 mRNA transporter, and constitutive NO synthase (cNOS), inducible NOS (iNOS), and arginase activity. Liver protein nitration increased more than 10-fold 24 h after LPS and an additional 2-fold in animals treated with GH before LPS. GH increased plasma NO(x) after LPS to levels 27% greater than those measured in non-GH-treated calves. LPS increased CAT-2 mRNA after LPS; GH was associated with a 24% reduction in CAT-2 mRNA content at the peak time response. cNOS activity was 3-fold greater than iNOS after LPS. NOS activities were increased 140% (cNOS) at 3 h and 169% (iNOS) at 6 h, respectively, after LPS; GH treatment increased cNOS activity and the phosphorylation of endothelial NOS after LPS more than 2-fold over that measured in non-GH-treated calves. The data suggest that an increased production of nitrated protein develops in the liver during low-level, proinflammatory stress, and nitration is increased by GH administration through a direct effect on the competing activities of NOS and arginase, modulatable critical control points in the proinflammatory cascade.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15044352     DOI: 10.1210/en.2004-0063

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  7 in total

1.  Temporal pattern changes in duodenal protein tyrosine nitration events in response to Eimeria acervulina infection in chickens.

Authors:  Ted H Elsasser; Kate Miska; Stanislaw Kahl; Raymond H Fetterer; Alfredo Martínez Ramirez
Journal:  J Anim Sci       Date:  2018-06-04       Impact factor: 3.159

2.  Lipopolysaccharide-induced hepatic oxidative injury is not potentiated by knockout of GPX1 and SOD1 in mice.

Authors:  Jian-Hong Zhu; Xin Gen Lei
Journal:  Biochem Biophys Res Commun       Date:  2010-12-08       Impact factor: 3.575

3.  Role of copper,zinc-superoxide dismutase in catalyzing nitrotyrosine formation in murine liver.

Authors:  Jian-Hong Zhu; Xiaomei Zhang; Carol A Roneker; James P McClung; Sheng Zhang; Theodore W Thannhauser; Daniel R Ripoll; Qi Sun; Xin Gen Lei
Journal:  Free Radic Biol Med       Date:  2008-05-28       Impact factor: 7.376

4.  Nitric oxide mediates prostaglandins' deleterious effect on lipopolysaccharide-triggered murine fetal resorption.

Authors:  J Aisemberg; C Vercelli; S Billi; M L Ribeiro; D Ogando; R Meiss; S M McCann; V Rettori; A M Franchi
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-25       Impact factor: 11.205

5.  Blastocystis tropism in the pig intestine.

Authors:  R Fayer; T Elsasser; R Gould; G Solano; J Urban; M Santin
Journal:  Parasitol Res       Date:  2014-02-18       Impact factor: 2.289

6.  Breed-specific differences in the immune response to lipopolysaccharide in ewes.

Authors:  Jessalyn M Hadfield; Elizabeth C Bowdridge; Ida Holásková; Ted H Elsasser; Robert A Dailey
Journal:  J Anim Sci       Date:  2018-09-29       Impact factor: 3.159

7.  AKT/eNOS signaling module functions as a potential feedback loop in the growth hormone signaling pathway.

Authors:  Cong-Jun Li; Theodore H Elsasser; Stanislaw Kahl
Journal:  J Mol Signal       Date:  2009-03-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.